Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Page 1
A population-level strain genotyping method to study pathogen strain dynamics in human infections.
Morgan SJ, Durfey SL, Ravishankar S, Jorth P, Ni W, Skerrett DT, Aitken ML, McKone EF, Salipante SJ, Radey MC, Singh PK. Morgan SJ, et al. Among authors: aitken ml. JCI Insight. 2021 Dec 22;6(24):e152472. doi: 10.1172/jci.insight.152472. JCI Insight. 2021. PMID: 34935640 Free PMC article.
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. ...
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. ...
Optimising inhaled mannitol for cystic fibrosis in an adult population.
Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM. Flume PA, et al. Among authors: aitken ml. Breathe (Sheff). 2015 Mar;11(1):39-48. doi: 10.1183/20734735.021414. Breathe (Sheff). 2015. PMID: 26306102 Free PMC article. Review.
Inhalation of mannitol as a dry powder is thought to change the viscoelastic properties of airway secretions, increase the hydration of the airway surface liquid and contribute to increased mucociliary and cough clearance of retained secretions. In two large phase 3 studies [1, 2 …
Inhalation of mannitol as a dry powder is thought to change the viscoelastic properties of airway secretions, increase the hydration of the …
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B; CF302 Investigators. Aitken ML, et al. Am J Respir Crit Care Med. 2012 Mar 15;185(6):645-52. doi: 10.1164/rccm.201109-1666OC. Epub 2011 Dec 28. Am J Respir Crit Care Med. 2012. PMID: 22198974 Clinical Trial.
RATIONALE: New treatment strategies are needed to improve airway clearance and reduce the morbidity and the time burden associated with cystic fibrosis (CF). OBJECTIVES: To determine whether long-term treatment with inhaled mannitol, an osmotic agent, improves lung functio …
RATIONALE: New treatment strategies are needed to improve airway clearance and reduce the morbidity and the time burden associated with cyst …
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Clancy JP, et al. Among authors: aitken ml. Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8. Thorax. 2012. PMID: 21825083 Free PMC article. Clinical Trial.
Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. CLINICAL TRIAL NUMBER: NCT00865904....
Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those me …
Pregnancy in cystic fibrosis.
Tonelli MR, Aitken ML. Tonelli MR, et al. Among authors: aitken ml. Curr Opin Pulm Med. 2007 Nov;13(6):537-40. doi: 10.1097/MCP.0b013e3282f01120. Curr Opin Pulm Med. 2007. PMID: 17901761 Review.
Underlying cystic fibrosis-related diabetes mellitus will likely become apparent and require intensified treatment, and weight gain may be difficult. Long-term outcome for women with cystic fibrosis does not appear to be negatively impacted by pregnancy. Indeed, cystic fib …
Underlying cystic fibrosis-related diabetes mellitus will likely become apparent and require intensified treatment, and weight gain may be d …
Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients.
Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR Jr, Dunitz J, Murray FT. Borowitz D, et al. Among authors: aitken ml. Pancreas. 2006 Apr;32(3):258-63. doi: 10.1097/01.mpa.0000202952.10612.21. Pancreas. 2006. PMID: 16628080 Clinical Trial.
At the other dosing levels, the mean coefficient of fat and nitrogen absorption increases were 19.1% +/- 24.9% and 17.8% +/- 13.6%, respectively, whereas the mean stool weight decreased by 517 +/- 362 g. CONCLUSIONS: TCT was well tolerated in this short-term exposure study …
At the other dosing levels, the mean coefficient of fat and nitrogen absorption increases were 19.1% +/- 24.9% and 17.8% +/- 13.6%, respecti …
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Mayer-Hamblett N, et al. Among authors: aitken ml. Am J Respir Crit Care Med. 2002 Dec 15;166(12 Pt 1):1550-5. doi: 10.1164/rccm.200202-087OC. Epub 2002 Aug 15. Am J Respir Crit Care Med. 2002. PMID: 12406843
Transplant referral decisions based either on a multivariate logistic model or on the criterion of an FEV1 of less than 30% predicted are likely to result in high rates of premature referral. Better clinical predictors of short-term mortality among patients with CF are nee …
Transplant referral decisions based either on a multivariate logistic model or on the criterion of an FEV1 of less than 30% predicted are li …
Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.
Goss CH, Otto K, Aitken ML, Rubenfeld GD. Goss CH, et al. Among authors: aitken ml. Am J Respir Crit Care Med. 2002 Aug 1;166(3):356-61. doi: 10.1164/rccm.2109078. Am J Respir Crit Care Med. 2002. PMID: 12153970
Although patients with CF who acquire S. maltophilia have more advanced disease than those who do not acquire this organism, detection does not independently affect short-term survival (3 years)....
Although patients with CF who acquire S. maltophilia have more advanced disease than those who do not acquire this organism, detection does …
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.
Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A. Aitken ML, et al. JAMA. 1992 Apr 8;267(14):1947-51. JAMA. 1992. PMID: 1548827 Clinical Trial.
CONCLUSIONS: Aerosolized rhDNase appears safe in normal subjects and in adults with cystic fibrosis and may improve lung function with short-term therapy....
CONCLUSIONS: Aerosolized rhDNase appears safe in normal subjects and in adults with cystic fibrosis and may improve lung function with short …